Please assess the completion status of the following clinical trial:

Trial Title: Mono Antiplatelet and Colchicine Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Successful PCI with drug-eluting stent for NSTE-ACS or STEMI~* Provision of written informed consent~Exclusion Criteria:~* Cardiac arrest or cardiogenic shock~* Age \<19 or \>90 years old~* Severe liver impairment~* Severe renal impairment (eGFR \<30 mL/min/1.73 m2)~* Atrial fibrillation requiring anticoagulation therapy~* Intolerance of prasugrel, ticagrelor, or colchicine~* History of intracranial hemorrhage~* Active bleeding

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Mono Antiplatelet and Colchicine Therapy (Type: EXPERIMENTAL): Aspirin-free, single P2Y12 inhibitor (prasugrel or ticagrelor) and colchicine treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).